BioticsAI secures FDA approval for AI ultrasound copilot to aid fetal abnormality detection

BioticsAI has obtained US Food and Drug Administration approval for its artificial intelligence copilot, a tool designed to assist clinicians in detecting fetal abnormalities during ultrasound examinations. The regulatory milestone marks a significant transition for the company, moving it from a development phase into active deployment within hospital settings.

Founded by CEO Robhy Bustami, the firm initially gained prominence by winning the TechCrunch Startup Battlefield in 2023 with a low-cost prototype. Despite this early success, the company adopted a rigorous development strategy from day one, integrating clinical validation and regulatory planning into its core product lifecycle rather than treating compliance as a post-build hurdle.

This disciplined approach involved early engagement with regulators through pre-submission meetings to align on study design and expectations. By working closely with clinicians and collecting large-scale datasets before the submission stage, the team navigated the often opaque regulatory process to secure clearance in January.

With approval now secured, BioticsAI is entering a deployment phase to roll out its technology in hospitals. The firm intends to expand its scope beyond obstetrics into broader areas of reproductive health, addressing high misdiagnosis rates that remain a critical issue in the industry.

Bustami noted that while the timeline for healthcare innovation is longer than in other sectors, the reward lies in building solutions that genuinely change how care is delivered. The company continues to foster a culture of alignment among engineers, clinicians, and researchers to maintain momentum throughout the long game of medical device development.